ATC Group: L04AE04 Ponesimod

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AE04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AE Sphingosine-1-phosphate (S1P) receptor modulators
5 L04AE04

Active ingredients in L04AE04

Active Ingredient Description
Ponesimod

Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator. Ponesimod binds with high affinity to S1P receptor 1 located on lymphocytes. It blocks the capacity of lymphocytes to egress from lymph nodes reducing the number of lymphocytes in peripheral blood. The mechanism by which it exerts therapeutic effects in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.

Related product monographs

Title Information Source Document Type  
PONVORY Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Italy (IT)

Lithuania (LT)

Poland (PL)

Romania (RO)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.